Recursion director proposes $125K share sale
The notice lists the shares as acquired from the issuer through a stock option exercise and sold for cash on October 6, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Recursion Pharmaceuticals, Inc. (RXRX) director Robert M. Hershberg gave notice of a proposed sale of 25,000 Class A shares on October 6, 2026, with an aggregate market value of $125,000. The notice lists the shares as acquired from the issuer through a stock option exercise and sold for cash through Fidelity Brokerage Services LLC. The issuer's shares outstanding are listed as 535,342,170.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.